FDA reopens the comment period on the Title 21 terminology proposal (FR Doc. 2026-15671)

Reopens for an additional 60 days — until 11:59 p.m. Eastern on October 2, 2026 — the comment period on the May 6, 2026 proposed rule to remove "gender" from Title 21 of the CFR. The stated reason is "to allow interested persons additional time to submit comments." The notice restates the substance of the underlying proposal: it "will remove the term 'gender' wherever it appears and either replace it with the term 'sex,' or delete reference to gender, as applicable, along with other editorial changes to improve readability." This is the most recent action in the terminology program and establishes that the government-wide scrub remains in active rulemaking as of the close of this chronology.